Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer is a phase 1/2 interventional study registered as NCT05739981 by Imunon, with 30 participants planned, started 2023-02-10 and due to reach its primary completion in 2027-06-30. Interventions recorded: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.